1. Home
  2. CYTK vs HOMB Comparison

CYTK vs HOMB Comparison

Compare CYTK & HOMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • HOMB
  • Stock Information
  • Founded
  • CYTK 1997
  • HOMB 1998
  • Country
  • CYTK United States
  • HOMB United States
  • Employees
  • CYTK N/A
  • HOMB N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • HOMB Major Banks
  • Sector
  • CYTK Health Care
  • HOMB Finance
  • Exchange
  • CYTK Nasdaq
  • HOMB Nasdaq
  • Market Cap
  • CYTK 5.6B
  • HOMB 5.0B
  • IPO Year
  • CYTK 2004
  • HOMB 2006
  • Fundamental
  • Price
  • CYTK $32.43
  • HOMB $27.63
  • Analyst Decision
  • CYTK Buy
  • HOMB Hold
  • Analyst Count
  • CYTK 14
  • HOMB 5
  • Target Price
  • CYTK $70.92
  • HOMB $31.00
  • AVG Volume (30 Days)
  • CYTK 1.3M
  • HOMB 653.3K
  • Earning Date
  • CYTK 08-07-2025
  • HOMB 07-16-2025
  • Dividend Yield
  • CYTK N/A
  • HOMB 2.91%
  • EPS Growth
  • CYTK N/A
  • HOMB 8.29
  • EPS
  • CYTK N/A
  • HOMB 2.09
  • Revenue
  • CYTK $19,218,000.00
  • HOMB $987,214,000.00
  • Revenue This Year
  • CYTK $18.02
  • HOMB $11.25
  • Revenue Next Year
  • CYTK $737.32
  • HOMB $2.78
  • P/E Ratio
  • CYTK N/A
  • HOMB $13.19
  • Revenue Growth
  • CYTK 412.21
  • HOMB 1.15
  • 52 Week Low
  • CYTK $29.31
  • HOMB $22.90
  • 52 Week High
  • CYTK $61.38
  • HOMB $32.91
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 46.32
  • HOMB 43.25
  • Support Level
  • CYTK $32.02
  • HOMB $27.29
  • Resistance Level
  • CYTK $34.72
  • HOMB $27.98
  • Average True Range (ATR)
  • CYTK 1.30
  • HOMB 0.47
  • MACD
  • CYTK 0.26
  • HOMB -0.11
  • Stochastic Oscillator
  • CYTK 45.08
  • HOMB 19.65

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About HOMB Home BancShares Inc.

Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality and a solid balance sheet. The bank's main source of net revenue is net interest income.

Share on Social Networks: